Eradication of breast cancer cells in patients with distant metastasis: the finishing touches? (Q37869838)

24 August 2017

1 reference

title

Eradication of breast cancer cells in patients with distant metastasis: the finishing touches? (English)

1 reference

24 August 2017

1

Yoshinori Ito

1 reference

24 August 2017

2

Takuji Iwase

1 reference

24 August 2017

3

Kiyohiko Hatake

1 reference

24 August 2017

28 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

19

1 reference

24 August 2017

3

1 reference

24 August 2017

206-211

1 reference

https://scigraph.springernature.com/pub.10.1007/s12282-011-0266-5

24 August 2017

0 references

cites work

The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

PARP inhibitor development for systemic cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Is breast cancer survival improving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Fifteen-year trends in metastatic breast cancer survival in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Survival differences among women with de novo stage IV and relapsed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Gene expression profiling of primary breast carcinomas using arrays of candidate genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Measuring proliferation in breast cancer: practicalities and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Ki67 in breast cancer: prognostic and predictive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Cancer stem cells and self-renewal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Breast cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

More than markers: biological significance of cancer stem cell-defining molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

The mammary gland "side population": a putative stem/progenitor cell marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Survivin, a cancer target with an emerging role in normal adult tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Overcoming drug resistance by enhancing apoptosis of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Targeting Hedgehog--a cancer stem cell pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Bmi-1, stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Targeting Wnt signaling: can we safely eradicate cancer stem cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Targeting Notch to target cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Mammary stem cells and breast cancer--role of Notch signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Hedgehog Pathway Antagonist 5E1 Binds Hedgehog at the Pseudo-active Site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Therapeutic antibody targeting of individual Notch receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Epithelial-mesenchymal transition in cancer development and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

The difficulty of targeting cancer stem cell niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Bone marrow cells in the 'pre-metastatic niche': within bone and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Resistance to endocrine therapy: are breast cancer stem cells the culprits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Stem cells: Cues from steroid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Progesterone induces adult mammary stem cell expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Control of mammary stem cell function by steroid hormone signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0266-5

10.1007/S12282-011-0266-5

21 January 2018

Identifiers

DOI

1 reference

release_jvzoqhpqynck3lqlqr7wnzuuue

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jvzoqhpqynck3lqlqr7wnzuuue

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

21526426

1 reference

PubMed ID

21526426